drugset / Trial / NCT02022930

Hydros and Hydros-TA Joint Therapy for Pain Associated With Knee Osteoarthritis

NCT02022930

Phase 3 Completed 510 enrolled Carbylan Therapeutics, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of Hydros-TA Joint Therapy for relief of pain due to OA of the knee. Hydros-TA is designed to provide fast acting and long lasting pain relief for up to six months with a single IA injection.

Timeline

Start
2014-01
Primary completion
2015-12
Completion
2016-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Triamcinolone Acetonide Other / unclassified

Indications